Trial
NCT00022490
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
OHSU Knight Cancer Institute
Collaborators
National Cancer Institute (NCI)
Condition
Leukemia
Intervention
cytarabine
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-01-07